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Whether a gene involved in distinct tissue or cell functions exerts a core of common
molecular activities is a relevant topic in evolutionary, developmental, and pathological
perspectives. Here, we addressed this question by focusing on the transcription factor and
regulator of chromatin accessibility encoded by the Cdx2 homeobox gene that plays
important functions during embryonic development and in adult diseases. By integrating
RNAseq data in mouse embryogenesis, we unveiled a core set of common genes whose
expression is responsive to the CDX2 homeoprotein during trophectoderm formation,
posterior body elongation and intestinal specification. ChIPseq data analysis also identified
a set of common chromosomal regions targeted by CDX2 at these three developmental
steps. The transcriptional core set of genes was then validated with transgenic mouse
models of loss or gain of function of Cdx2. Finally, based on human cancer data, we
highlight the relevance of these results by displaying a significant number of human
orthologous genes to the core set of mouse CDX2-responsive genes exhibiting an altered
expression along with CDX2 in human malignancies.
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INTRODUCTION
That evolution makes new out of old suggests the existence of shared properties between the
functions of a given gene at its different times or sites of action. The homeobox gene encoding
the CDX2 transcription factor allows addressing this assumption since it drives three major
developmental processes in mammals. At the blastula stage, Cdx2 is pivotal during the
segregation of pluripotent cells into the first two lineages by acting downstream of the
lineage allocation process between trophectodermal and inner mass cells to repress Oct4 and
Nanog in the trophectoderm (Niwa et al., 2005; Strumpf et al., 2005; Ralston and Rossant, 2008).
Then, Cdx2 actively participates in axial posterior body growth at gastrulation through a
convergent effect with T-Brachyury to maintain stemness properties of neuro-mesodermal axial
progenitors and to sustain Fgf and Wnt signaling (van Rooijen et al., 2012; Amin et al., 2016).
Finally, Cdx2 determines intestinal identity of the mid-/hindgut endoderm in embryos and
allows identity maintenance of the adult gut epithelium by regulating the proliferation of stem/
progenitor cells and the differentiation of mature enterocytes (Gao et al., 2009; Verzi et al., 2010;
Stringer et al., 2012). Molecularly, the CDX2 protein has been shown to bind the proximal
promoter of a number of target genes, as first uncovered with the intestinal sucrase-isomaltase
gene (Suh et al., 1994). In addition, it also binds distant chromatin regions to prevent epigenetic
silencing and keep chromatin domains open and active (Saxena et al., 2017).
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While physiologically restricted to the gut epithelium in
adults, CDX2 expression becomes reduced and heterogeneous
in human colorectal cancer, particularly in tumors with the
worst prognosis (Baba et al., 2009; Dalerba et al., 2016; Balbinot
et al., 2018). This reduction facilitates tumor progression, as
shown in mouse models of intestinal cancer, indicating a tumor
suppressor role in the gut (Bonhomme et al., 2003; Sakamoto
et al., 2017; Balbinot et al., 2018). Inversely, CDX2 is ectopically
turned on outside the gut in precancerous intestine-type
metaplasia and associated adenocarcinoma of foregut-derived
organs including stomach and esophagus (Moskaluk et al.,
2003), even though patients survival correlates with the
CDX2 level in gastric cancers (Seno et al., 2002). Beside the
upper digestive tract, CDX2 is also ectopically expressed in 80%
of acute myeloid leukemia (AML) irrespective of the cytogenetic
group but correlating with disease burden (Scholl et al., 2007).
Thus, unlike the gut, CDX2 has on oncogenic effect in the
hematopoietic lineage, as recently demonstrated in mice (Vu
et al., 2020; Galland et al., 2021).
On this basis, the present work interrogates whether some
elements of the response to CDX2 are shared during the
successive steps of embryonic development in mice and
subsequently whether these elements are altered in human
pathologies along with CDX2.
RESULTS
A Core Set of Genes Responsive To CDX2
During Mouse Development
To address if there is a common set of genes responsive to the
CDX2 transcription factor during its successive functions in
mouse embryogenesis, we analyzed publicly available RNAseq
data related to trophectoderm formation, posterior growth, and
intestinal fate determination (see Supplementary Table S1.1).
For this purpose, we compared the consequences of Cdx2
overexpression in embryonic stem (ES) cells (Cambuli et al.,
2014; Rhee et al., 2017), of Cdx loss of function in E8 growing
embryos (Amin et al., 2016), and of Cdx2 deficiency in the
intestinal endoderm of E16 embryos (Banerjee et al., 2018).
With |log2fold-change|>2 and p < 0.05, a core set of 221
differentially expressed murine genes (DEGs), corresponding
to 162 human orthologues, was identified in common between
these three conditions (Figure 1A; Supplementary Table S1.2).
Interestingly, the up or down expression changes of the DEGs
were not always consistent at the three developmental steps,
indicating a context-dependent response to CDX2 (Figure 1B;
Supplementary Table S1.3). Ontology enrichment analysis of the
162 human orthologues revealed a significant association with
“extracellular exosome”, “extracellular matrix”, “multicellular
FIGURE 1 | A core set of DEGs responsive to CDX2 in mouse development. (A) Comparison of differentially expressed genes between Cdx2-overexpressing vs
wild type ES cells (trophectoderm formation; blue), E8 Cdx-null vs wild type embryos (posterior growth, AP patterning; yellow) and intestinal epithelial cells of E16 Cdx2−/−
vs wild type embryos (gut specification; green) showing the core set of 221 mouse DEGs. (B) Correlation map of the expression changes of the mouse core set of 162/
221 DEGs having human orthologues, at the three developmental steps (yellow: up-regulation; blue: down-regulation): trophectoderm formation (Troph; Cdx2-
overexpressing vs wild type ES cells), posterior growth (Post Grth; E8 wild-type vs Cdx-null embryos) and gut specification (Gut; E16 wild-type vs Cdx2−/− embryos). At
each developmental stage, the map illustrates the comparison of the Cdx2-expressing samples vs the Cdx2 non-expressing counterparts. The arrowhead shows CDX2.
(C) Ontology analysis of the set of 162 human orthologues to the mouse core set of DEGs. **p < 0.01, ***p < 0.001.
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organism development”, “sequence-specific DNA binding”,
“gene regulation”, “metabolic process” and “Wnt signaling”
(Figure 1C; Supplementary Table S1.4). Twenty-eight genes
of the DEGs core encoded nuclear proteins involved in chromatin
conformation, DNA transcription and repair (Arid3a, Bmyc,
Cdx1, Cdx2, Commd3, Ets2, Gata4, Hmgn3, Hoxb1, Hoxb5,
Hoxc5, Hoxc6, Hoxc8, Id2, Id3, Nkx1.2, Pbx1, Prickle1, Prr13,
Pitx1, Rcor2, Smarca1, Sox2, Sp5, Tbx4, Tfeb, Tlx2, Znf503), of
which 11 homeobox genes known to play important roles in
morphogenesis (underlined). Taken together, these results
demonstrate the existence of a core set of genes responsive to
CDX2 during its successive functions in embryonic development.
A Core Set of Chromatin Sites Bound by
CDX2 During Mouse Development
Next, publicly available ChIPseq data (Amin et al., 2016; Rhee et
al., 2017; Banerjee et al., 2018) were used to compare the location
of the CDX2 protein on chromatin at the three developmental
stages analyzed above by RNAseq. It gave a core set of 1,047
chromosomal regions sharing overlapping peaks in the three
conditions (Figure 2A; Supplementary Table S2.1). 265 and 466
of these peaks respectively fell into protein coding genes and their
promoters (defined as the 2-kb segment upstream of the
transcription start site), 52 into non-protein coding genes and
their 2-kb promoters, and 264 into intergenic regions. Among the
1,047 regions, 835 (77.75%) exhibited at least one conservedmotif
analogous to the mouse CDX2 binding site reported in the
JASPAR database (#PH0013.1), based on the functional
characterization of CDX-binding sites by SELEX (T/C-A-T-A-
A-A-T/G, Margalit et al., 1993). This gave a total of 1,801 CDX-
type sites (enrichment p-value  10−152) (Figure 2B;
Supplementary Table S2.2). Interestingly, the ± 50 bp
segments around these CDX-type sites were enriched in DNA-
binding motifs for 149 transcription factors (p < 0.05) grouped
into 25 families (Figure 2C; Supplementary Table S2.3).
Moreover, 71 of these transcription factor binding motifs (p <
0.05), belonging to nine families, were also enriched within
the ± 50 bp segments centered on the 1,314 CDX-type sites
present in the promoters of the 221 DEGs (Figure 2C;
Supplementary Table S2.2 and Supplementary Table S2.4).
The presence of enriched binding motifs for these
transcription factors nearby the CDX binding sites suggests
possible direct or indirect interactions. Among the CDX2
ChIPseq peaks located in gene promoters, 8 were associated
with genes of the core set of DEGs (Arid3a, Epha4, Hoxc6,
Man1c1, Mgat1, Mid1ip1, Sgsm1, Tfeb), whereas 75 out of the
264 intergenic peaks (28.41%) fell into Super-Enhancer domains
(Supplementary Table S2.5).
Validation of the Core Set of Differentially
Expressed Murine Genes in Independent
Transgenic Mouse Models
Five transgenic mouse models targeting the Cdx2 gene have
been reported together with corresponding RNAseq data: 1)
the ectopic expression of human CDX2 in the anterior
epiblast at gastrulation (RsCDX2:Sox2CreERT2 embryos)
FIGURE 2 |ChIPseq targets of CDX2 during mouse development. (A) Comparison of the CDX2-associated chromosomal regions during trophectoderm formation
(trophectoderm formation; blue), embryonic posterior elongation (posterior growth, AP patterning; yellow) and gut formation (gut specification; green) showing the core
of 1,047 common regions. (B) Consensus sequence of the 1801 CDX-type motifs present in the 1047 CDX2-bound chromosomal regions. (C) Enrichment in consensus
binding motifs for the indicated transcription factors in the vicinity (+/50 bp) of the 1801 CDX-type sites present in the common ChIPseq regions (yellow) and in the
vicinity of the 1340 CDX-type sites present in the promoters of the 221 common DEGs (blue). *p < 0.05, **p < 0.01, ***p < 0.00001. HD: homeodomain; Zf: zinc finger; h:
hormone.
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resulting in severe head dysgenesis (HdDys) (Grall et al.,
2019); 2) the sporadic silencing of the single wild type Cdx2
allele in heterozygous Cdx2+/− embryos leading to congenital
gastric-type heteroplasia in the cecum (GastHet) (Beck et al.,
1999; Balbinot et al., 2018); 3) the mosaic invalidation of
Cdx2 in the adult intestinal epithelium (AhCreERT:Cdx2f/f
mice) inducing pericecal gastric-type metaplasia (GastMeta)
(Balbinot et al., 2018); 4) the ectopic expression of mouse
Cdx2 in hematopoietic stem cells (SclCreERT:Rosa-LSL-Cdx2
mice) leading to myelodysplasia (MyeloDys) (Vu et al., 2020),
and 5) the ectopic induction of human CDX2 in bone marrow
stem/progenitor cells (Mx1Cre:RsCDX2 mice) inducing
monoblastic leukemia (MnLK) (Galland et al., 2021).
Testing the deregulated genes in these five murine models
against the 162 human orthologues to the mouse core set of
DEGs revealed a significant number of genes in common,
namely 28 genes in HdDys (enrichment p-value  5.030 E−15),
82 genes in GastHet (enrichment p-value  3.020 E−12), 109
genes in GastMeta (enrichment p-value  3.020 E−12), 45
genes in MyeloDys (enrichment p-value  4.324 E−5) and
49 genes in MnLK (enrichment p-value  1.546 E−4) (Figures
3A,B; Supplementary Tables S3.1–5). These results validate
the core set of DEGs responsive to CDX2 in mice. In addition,
they reinforce the notion of context-dependent effect.
Pattern of the Core Set of Differentially
Expressed Murine Genes in Human
Pathologies
Having established and validated the core set of DEGs in mice, we
addressed the pattern of the 162 orthologues in human diseases
exhibiting alterations in CDX2 levels (Figure 4A; Supplementary
Tables S4.1–2). Several pathological conditions were considered.
First, given that the physiological expression of CDX2 is limited
to the gut epithelium in adults and that it is reduced in colon
cancers with bad prognosis (Balbinot et al., 2018), we compared
the transcriptomes in the deciles of tumors exhibiting the lowest
vs highest CDX2 levels (n  44 each) among The Cancer Genome
Atlas (TCGA) collection of 436 colon adenocarcinomas (COAD).
Overall, a total of 46 genes among the 162 human orthologues of
the core set of DEGs were differentially expressed between both
groups (enrichment p-value  0.044) (Figures 4B,C;
Supplementary Table S4.3). Second, we considered
pathological situations exhibiting abnormal ectopic expression
of CDX2 outside the gut in the upper digestive tract, namely the
esophagus and stomach, where ectopic CDX2 associates with
precancerous metaplasia and adenocarcinoma (Moskaluk et al.,
2003). In the esophagus, retrieving the list of differentially
expressed genes between healthy CDX2-free mucosa (n  17)
FIGURE 3 | Validation of the core set of DEGs in transgenic mousemodels. (A) Enrichment analysis of 162/221 genes of the mouse core set of DEGs having human
orthologues in Cdx2-dependent transgenic mouse models of head dysgenesis (HdDys), gastric-type heteroplasia in the cecum (GastHet), gastric-type metaplasia in the
pericecal region (GastMeta), myelodysplasia (MyeloDys) andmonoblastic leukemia (MnLK). p-values are a  5.030 E−15; b  3.020 E−12; c  1.578 E−18; d  4.324 E−5; e
 1.546 E−4. (B) Correlation map of the above 162 genes of the mouse core set of DEGs in the validation models (yellow: up-regulation; blue: down-regulation). In
each case, themap illustrates the comparison of the Cdx2-expressing samples vs the Cdx2 non-expressing counterparts. The arrowhead showsCDX2. The order of the
genes is the same as in Figure 1B.
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and CDX2-expressing non-dysplastic Barrett metaplasia
(ESOBA-nd) (n  14), low-grade dysplastic Barrett metaplasia
(ESOBA-lgd) (n  8) and adenocarcinoma (ESOAD) (n  12)
(Maag et al., 2017) revealed respectively 123, 118 and 116
orthologues of the core set of DEGs (respective enrichment
p-values are 0.16 E−73, 0.21 E−64 and 0.96 E−44) (Figures 4B,C;
Supplementary Table S4.4–6). In the stomach, the list of
differentially expressed genes in the quartiles of tumors
presenting the highest vs lowest levels of CDX2 (n  35 each)
within the series of 272 STOAD samples of the TCGA comprised
44 DEGs of the core (enrichment p-value  0.0028) (Figures
4B,C; Supplementary Table S4.7). Third, we analyzed AML in
which abnormal ectopic expression of CDX2 is associated with
disease burden (Scholl et al., 2007). We found 35 genes of the core
set of DEGs among the genes differentially expressed between the
quartiles with the highest vs lowest levels of CDX2 (n  38 each)
in the series of 151 AML of the TCGA (enrichment p-value 
0.14 E−4) (Figures 4B,C; Supplementary Table S4.8). Taken
together, these results indicate that a significant proportion of
members of the core set of CDX2-responsive genes defined
during mouse development is differentially expressed in
human diseases along with CDX2 changes.
DISCUSSION
This study identified in mice a core set of common DEGs
responsive to the CDX2 homeoprotein and a core set of
common chromatin sites bound to the CDX2 protein at three
developmental steps at which this transcription factor plays
pivotal roles: trophectoderm specification, posterior growth of
the embryonic body and intestinal determination. The core of
DEGs was validated in transgenic mouse models targeting Cdx2.
Moreover, a significant number of human orthologues to the
mouse core set of DEGs was altered in humanmalignancies along
with CDX2. Taken together, these results show that a
transcription factor, e.g., the CDX2 homeoprotein, while
driving distinct functions at different steps during embryonic
development, can exert a common subset of molecular activities,
and that some of these activities can be subsequently deregulated
in adult pathologies along with this factor.
Although studies in mice have highlighted the importance of
the Cdx2 gene at many embryonic stages, developmental defects
linked to alterations of this gene are rare in human, likely because
its constitutive loss of function is expected to prevent
trophectoderm formation and uterine implantation of the
FIGURE 4 | Human orthologues to the core set of mouse DEGs deregulated in diseases. (A) Volcano plots of the differentially expressed genes in colon
adenocarcinoma (COAD), in esophageal non-dysplastic Barrett metaplasia (ESOBA-nd), low-grade dysplastic Barrett metaplasia (ESOBA-lgd) and adenocarcinoma
(ESOAD), in gastric adenocarcinoma (STOAD) and in acute myeloid leukemia (AML); up-regulated (yellow), down-regulated (blue), not significant (grey). (B) Enrichment
analysis of the set of 162 human orthologues to the mouse core set of DEGs among the differentially expressed genes in human diseases. p-values are a  0.044; b
 0.16 E−73; c  0.21 E−64; d  0.96 E−44; e  0.0028; f  0.14 E−4. (C) Correlation map of the expression changes of the human orthologues to the mouse core set of
DEGs in human diseases (yellow: up-regulation; blue: down-regulation). In each case, the map illustrates the comparison of the CDX2-high expressing samples vs
CDX2 non-expressing or low-expressing counterparts. The arrowhead shows CDX2. The order of the genes is the same as in Figure 1B.
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blastula. However, human CDX2 gene variants have recently
been associated with sirenomelia (Lecoquierre et al., 2020), in
accordance with the function attributed to this gene in posterior
body elongation and patterning. Moreover, the aberrant
expression of CDX2 reported in various forms of congenital
endoderm-derived heteroplasia corroborates its key role in
intestinal identity determination (Martin et al., 2010). Beyond
embryogenesis, pathological alterations of CDX2 levels occur at
its physiological site of expression, the gut, as well as ectopically in
the upper digestive tract and in leukemia. The fact that the
expression of a significant number of genes of the
developmental core set of DEGs changed along with CDX2 in
humanmalignancies strengthens the relevance of this DEGs core.
This study reveals that the direction of the changes of several
genes of the DEGs core is not consistent at the three mouse
developmental steps analyzed here, as well as in human
pathologies. It emphasizes the context-dependent activity of
this transcription factor. This property can be seen in view of
the number of CDX2 ChIPseq peaks overlapping intergenic
Super Enhancers known to control the functional activity of
large chromosomal regions, and of the anti-repressing effect
exerted by the CDX2 protein to prevent the incursion of
inactive marks into chromatin domains and keep them
accessible to other transcription partners (Verzi et al., 2013;
Saxena et al., 2017). Thus, as shown in the gut, CDX2 can
have inductive, permissive and repressive transcriptional
effects (Verzi et al., 2013; San Roman et al., 2015; Saxena
et al., 2017), indicating that its outcome depends not only on
the chromatin domains that are kept open, but also on the specific
repertoire of nuclear partners present in the cells and able to
interact with open chromatin regions to either stimulate or
inhibit transcription. Interestingly, in pathological situations
the context-dependent activity of CDX2 could provide hints to
explain opposite effects, being a tumor suppressor in its
physiological site of expression, the gut, but an oncogene
when ectopically expressed in the hematopoietic lineage. Thus,
the present study opens ways to investigate novel functional
interactions between developmental genes and exploit them in
a therapeutic perspective.
MATERIALS AND METHODS
Mouse and Human RNAseq and ChIPseq
Data
Mouse RNAseq and ChIPseq data were retrieved from the GEO
database (https://www.ncbi.nlm.nih.gov/geo/): GSE62149
(Cambuli et al., 2014) and GSE90752 (Rhee et al., 2017) for
ES cells, GSE84899 (Amin et al., 2016) for E8 growing embryos,
GSE115541 (Banerjee et al., 2018) for E16 intestinal endoderm,
GSE123559 (Grall et al., 2019) for the head dysgenesis model,
GSE89992 (Balbinot et al., 2018) for gastric-type intestinal
hetero- and metaplasia, GSE133679 (Vu et al., 2020) for
myelodysplasia, and GSE120487 (Galland et al., 2021) for
monoblastic leukemia. The identifiers of samples used for this
study are given in the Supplementary Table S1.1. Human
RNAseq data from colon adenocarcinoma (COAD), stomach
adenocarcinoma (STOAD) and acute myeloid leukemia (AML)
were obtained from the database The Cancer Genome Atlas (The
TCGA research network: https://www.cancer.gov/tcga) with the
identifiers given in Supplementary Table S4.1. Esophageal
metaplasia and adenocarcinoma data were from Maag et al.
(2017).
Mouse mRNAseq Read Mapping and
Quantification of Expression
Quality controls of raw RNAseq reads were carried out with the
FASTX toolkit (http://hannonlab.cshl.edu/fastx_toolkit/index.
html) to assess base quality, nucleotide ratio and sequence
duplication rate. RNAseq reads were then mapped with STAR
(Dobin et al., 2013) against the mouse reference genome
GRCm38. Alignments were filtered in normal mode and
multi-mapped reads were discarded. For every splicing
junction reconstructed from the first round of mapping, a
second mapping was carried out to improve alignment.
Metrics on alignment were computed with Samtools Flagstat
and Samtools Stat (Danecek et al., 2021) to ensure quality of
mapping. Raw gene expression, i.e. the number of mapped reads
per annotated gene, were computed with HTSeq, in union mode
and with the annotation of the reference genome provided as a
GTF file.
Mouse CELseq Read Mapping and
Quantification of Expression
For the CELseq data of growing mouse embryos (Amin et al.,
2016), sequencing adapters were trimmed with Cutadapt (Martin,
2011). Reads were mapped on the reference genome GRCm38
with BWA.aln (Li et al., 2009) and genomic coordinates were
converted to alignment with BWA Samse and Samtools view.
Raw read numbers were computed as described above for
mRNAseq data.
Differential Expression Analysis
For mouse ES cells data, as no replicate was available, differential
expression was assessed by computing the delta of the gene
expression values between control and experimental condition
in each of the two datasets (Rhee et al., 2017 and Cambuli et al.,
2014). Then, common differentially expressed genes between
both datasets were selected with a threshold of 2 on delta. For
the other mouse embryos data, namely the growing embryo
(Amin et al., 2016) and the intestinal endoderm (Banerjee
et al., 2018), DESeq2 (Love et al., 2014) was used. Gene
expression was normalized with a regression model and
differential expression was tested with the Wald test corrected
by Bonferonni. False positives were identified with the Cook
distance and flagged. Samples segregation was assessed by
Principal Component Analysis (PCA, Supplementary Figure
S1). Genes with significant variations in transcript levels were
selected applying a threshold of 2 on |log2 (fold-change)| and a
threshold of 0.05 on adjusted p-value. These genes were then
compared between the datasets of the three developmental stages,
i.e., ES cells, growing embryo and gut endoderm, to create the
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core set of common differentially expressed genes (DEGs). The
enrichment in genes of the core was tested with the exact Fisher
test. Orthology between the mouse DEGs and the human genome
was evaluated with Ensembl Compara information based on the
annotation of the mouse reference genome GRCm38, with a
confidence score of 1 (high) or a minimal sequence homology of
30%, using a custom-made R-script as previously published
(Mayrhofer et al., 2017). Enriched biological functions (Gene
Ontology Resource, http://geneontology.org/), signaling
pathways (Kyoto Encyclopedia of Genes and Genomes, https://
www.genome.jp/kegg/) and protein domains (InterPro, http://
www.ebi.ac.uk/interpro/) were tested on the core set of genes with
DAVID (Huang et al., 2009). Further annotation of genes
including symbol and description were collected with a
custom-made R script.
Mouse ChIPseq Data Processing
ChIPseq reads were mapped with BWA (Li and Durbin, 2009)
against the reference genome GRCm38 as described above for the
CELseq data. Unmapped reads, reads with low mapping quality,
i.e., a Phred score below 30 for each base, and multi-mapped
reads were filtered out. Duplicated reads were removed with
GATK MarkDuplicates (Van der Auwera and O’Connor, 2020).
Metrics on alignments were collected with Samtools Stats and
Samtools Flagstat to ensure a good quality of read mapping
(Danecek et al., 2021). Peaks were detected with MACS2
(Zhang et al., 2008). A cutoff of 10−05 was set on p-values to
output peaks and significance of peaks compared to background
noise was evaluated with regard to the input control. For each
peak the signal was normalized computing fragment pileup per
million reads. ChIPseq peaks were then selected applying a
threshold of 0.05 on p-values and visually controlled in the
genome browser IGV (Robinson et al., 2011). A core was
created with ChIPseq peaks of the compared datasets
overlapping with at least 10 bp in the three conditions:
trophectoderm formation, antero-posterior patterning and gut
specification. ChIPseq peaks were annotated with an in-house
developed R script based on genes present in the annotation of the
reference genome GRCm38. Both upstream and downstream
genes were annotated. Intergenic ChIPseq peaks were further
compared to Super-Enhancers from the database dbSUPER
(Khan and Zhang, 2016).
DNA Binding Sites Analysis
All known binding motifs of vertebrate transcription factors
present in the core of ChIPseq peaks and in the gene
promoters of the core of DEGs (defined as the 2-kb
segment upstream of the canonical transcription start
site(s) of each gene) were retrieved from the database
JASPAR (Khan et al., 2018), classified with TFclass relying
on “class” and “family” subdivisions (Wingender et al., 2018),
and their position weight matrixes were reformatted.
Enrichment for transcription factor binding motifs was
tested with HOMER (Heinz et al., 2010) in the direct
vicinity (+/− 50 bp) of mapped CDX-type homeobox
motifs identified in the promoters of the DEGs and in the
overlapping ChIPseq peaks. To test transcription factor
binding motif enrichment, background sets of DNA
sequences were created. These sets were composed of the
same number of tested regions, i.e., promoters or overlapping
ChIPseq peaks. The DNA sequences were of the same size as
the tested regions and were randomly extracted from the
mouse reference genome GRCm38.
Analysis of Mouse Validation Samples and
Human Pathological Samples
For samples obtained from mouse models of embryonic head
dysgenesis (Grall et al., 2019), gastric-type heteroplasia and
metaplasia (GastHet and GastMeta, Balbinot et al., 2018),
myelodysplasia (MyeloDys, Vu et al., 2020) and monoblastic
leukemia (MnLK, Galland et al., 2021), the log2 (fold-change)
and p-value were retrieved from the literature.
For human pathological samples, raw levels of transcripts were
computed with HTSeq (Anders et al., 2015) for colon
adenocarcinoma (COAD), stomach adenocarcinoma (STOAD)
and acute myeloid leukemia (AML). Each human gene symbol
was associated to the corresponding Ensembl gene identifier and
the transcript levels were normalized by computing reads per
kilobase per million in order to identify groups with high and low
levels of CDX2 transcripts. These groups were defined as upper
and lower quartiles or deciles with a purpose of comparable size.
For pair-wise comparison of groups, raw levels of transcripts were
processed with DESeq2 (Love et al., 2014) as described above.
Genes with significant variation in transcript levels were selected
applying a threshold of 0.05 on adjusted p-value (Bonferroni
multiple testing method). The significance of the difference in
expression level of CDX2 among samples with high versus low
expression of CDX2 in COAD, STOAD and AML is shown in the
boxplot of the Supplementary Figure S2 and confirmed with a
Wilcoxon test. For Barrett’s syndrome and esophagus
adenocarcinoma, log2 (fold-change) and p-value were retrieved
from the literature (Maag et al., 2017). For pathologies and
validation datasets, the enrichment in gene of the core was
tested with the one-tailed exact Fisher test with gene sets
defined by significantly differentially expressed genes and a
stringent gene Universe defined as genes confidently associated
with a Gene Ontology.
R-Scripts Availability




Publicly available RNAseq and ChIPseq datasets, clearly referred
in the article, were used for this study.
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